Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients

Summary

The study evaluates the safety and efficacy of Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients. The researchers hypothesize that additional Mesenchymal Stem Cell infusion can benefit the promising clinical islet transplantation through the following mechanisms: protection of islet from inflammatory damage, immunological modulation, engraftment promotion, thus decrease or eliminate the need of exogenous insulin and improve β-cell function.

Timeline

Start

2008-01

Primary completion

2012-01

Completion

2014-01

Drugs

Indications